Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
- 1 January 2009
- journal article
- review article
- Published by Informa UK Limited in Scandinavian Journal of Gastroenterology
- Vol. 44 (7), 782-786
- https://doi.org/10.1080/00365520902745039
Abstract
Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future.Keywords
This publication has 29 references indexed in Scilit:
- Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory responseScandinavian Journal of Gastroenterology, 2007
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Impact of gemcitabine on the treatment of metastatic pancreatic cancerJournal of Gastroenterology and Hepatology, 2005
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinomaHPB, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- The Cost of Treating Pancreatic CancerActa Oncologica, 2003
- Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)Drug Resistance Updates, 2002
- Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumoursBiochemical Pharmacology, 1994
- 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell linesBiochemical Pharmacology, 1993